سعر تولفون Tolvon‏ 30مجم 10 اقراص 2026

Mianserin 30 mg film-coated tablets (Tolvon; Sedico under licence of Schering-Plough, Egypt), tetracyclic antidepressant; pack of 10.

• Common: weight gain, sedation at start of treatment, raised liver enzymes, oedema. Uncommon: altered glucose tolerance, restlessness, sleep disturbance, dizziness, sweating, tremor, hypotension, erythema multiforme, arthralgia, gynaecomastia, galactorrhoea. Rare: blood dyscrasias (agranulocytosis, aplastic anaemia, thrombocytopenia), hypomania, convulsions, jaundice, bradycardia after initial dose.International label, same formulation · Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)

• Hypersensitivity; mania; acute intoxication with alcohol, hypnotics, analgesics or psychotropics; severe liver disease (e.g. cholestatic jaundice, hepatitis), liver cell tumours, Rotor and Dubin-Johnson syndromes; acute delirium; concomitant MAO inhibitors.International label, same formulation · Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)

• Bone marrow depression (granulocytopenia or agranulocytosis), usually within 4-6 weeks of starting and more common in the elderly; check white blood count before treatment; stop and do a full blood count if fever, sore throat, stomatitis or other signs of infection occur.International label, same formulation · Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)
• Suicidal thoughts and behaviour: monitor closely, especially early in treatment and after dose changes; increased risk in patients under 25 years; supply a limited number of tablets.International label, same formulation · Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)
• QT prolongation and ventricular arrhythmias including torsades de pointes reported; use cautiously with risk factors; correct hypokalaemia/hypomagnesaemia; stop or reduce dose if QTc >500 ms or increases by >60 ms.International label, same formulation · Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)

• AlcoholMianserin may potentiate CNS depressant effect of alcohol; avoid alcohol.Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)
• MAO inhibitors (e.g. moclobemide, tranylcypromine, linezolid)Do not use together or within 2 weeks of stopping an MAOI (and vice versa).Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)
• Coumarin anticoagulants (e.g. warfarin)May alter coumarin metabolism; monitoring required.Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)

• Animal and limited human data show no fetal or neonatal harm, but use in pregnancy only on strict medical indication after careful benefit-risk assessment.International label, same formulation · Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)
• Excreted in negligible amounts in breast milk; if use during breastfeeding is necessary, breastfeeding should be stopped.International label, same formulation · Organon Austria (marketing authorisation holder document; Austrian BASG authorisation)